A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML

This trial is testing a boosted version of venetoclax (combined with cobicistat, which helps raise venetoclax blood levels) plus azacitidine for people newly diagnosed with acute myeloid leukemia (AML) who are either not fit for intensive chemotherapy or prefer to avoid it. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with AML (excluding a type called acute promyelocytic leukemia) - You are not suitable for or choose to decline intensive (standard) chemotherapy - You are in reasonably good health (WHO performance status 0–2) - Your kidney and liver function are within acceptable limits **You may NOT be eligible if...** - You have acute promyelocytic leukemia (APL/M3) - You are fit and willing to receive intensive chemotherapy - You are currently taking strong medications that interact with venetoclax or cobicistat - You are pregnant or breastfeeding, or not using contraception Talk to your doctor to see if this trial is right for you.